About Contact Us Careers

Diagnostic Biomarkers Market Size & Share, by Product (Consumable, Software, Service); Application (Oncology, Metabolic Disease, Neurological Disease); End-user (Hospitals, Academic Research Institutes, Diagnostic Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3086
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Diagnostic Biomarkers Market size was over USD 62.43 billion in 2024 and is projected to reach USD 263.08 billion by 2037, witnessing around 11.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of diagnostic biomarkers is assessed at USD 68.64 billion.

The growth of the market can be attributed to the rising prevalence of diseases, such as, cancer, and diabetes, combined with the increasing demand for early diagnosis of such disease. Early diagnosis can significantly reduce the risk of complications and improve the chances of recovery. According to a report by the World Health Organization (WHO), cancer caused over 10 million deaths in 2020. The major type of cancers included lung, colon-rectal, liver and breast cancer, which are all treatable, if diagnosed on time. Lung cancer was the cause of 1.80 million deaths, whereas 935 000 deaths were caused by colon and rectum cancer; liver cancer was responsible for 830 000 deaths of the total deaths and breast cancer caused 685000 deaths. Moreover, rising demand for advanced treatment options and growing R&D investment for medical research, are estimated to further boost the market growth.

Growth Drivers

  • Increasing Demand for Early Diagnosis
  • Advancement in Diagnostic Technology

Challenges

  • High Cost of Diagnostic Biomarkers

Diagnostic Biomarkers Market: Key Insights

Report Attribute Details

Base Year

2024

Forecast Year

2025-2037

CAGR

11.7%

Base Year Market Size (2024)

USD 62.43 billion

Forecast Year Market Size (2037)

USD 263.08 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Diagnostic Biomarkers Segmentation

The market is segmented by product into consumable, software, and service, out of which, the consumable segment is anticipated to hold the largest share in the market during the forecast period on account of easy availability and affordable process of consumables, as compared to screening devices, and other biomarkers. On the basis of application, the market is segmented into oncology, metabolic diseases, neurological diseases, and others, out of which, the oncology segment is anticipated to attain notable growth during the forecast period, on the back of increasing cases of cancer globally, along with high mortality rate associated with cancer. As per other statistics of the WHO, cancer is the second leading cause of death globally, accounting for almost 9.6 million deaths, in the year 2018.

Our in-depth analysis of the global market includes the following segments:

           Product
  • Consumable
  • Software
  • Service

             Application
  • Oncology
  • Metabolic Disease
  • Neurological Disease
  • Others

 

 

           End-Use
  • Hospital
  • Academic Research Institute
  • Diagnostic Center
  • Others
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Diagnostic Biomarkers Industry - Regional Synopsis

 North America industry is likely to account for largest revenue share by 2037, impelled by efficient healthcare sector, supported by high government investment.The market in North America industry is set to hold largest revenue share by 2037, impelled by efficient healthcare sector, supported by high government investment. Moreover, technological advancement, increasing funding for R&D activities, and development of novel diagnostic tools, is estimated to boost the market growth. The market in the Asia Pacific region is estimated to witness highest CAGR over the forecast period on account of increasing prevalence of cancer and other chronic diseases, along with the developing healthcare sector and economic development in the region.

Global-Diagnostic-Biomarkers-Market-Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Companies Dominating the Diagnostic Biomarkers Landscape

    • Siemens Healthcare GmbH
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PerkinElmer Inc.
    • Biomarker Technologies, Inc.
    • Almac Group Limited
    • Myriad Genetics, Inc.
    • F. Hoffmann-La Roche Ltd
    • Epigenomics AG
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • QIAGEN GmbH

Recent Developments

  • November 16, 2020: PerkinElmer Inc. announced to launch new biomarker software solutions HPLC and UHPLC to accelerate and streamline lab testing.
  • Report ID: 3086
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of diagnostic biomarkers is assessed at USD 68.64 billion.

Diagnostic Biomarkers Market size was over USD 62.43 billion in 2024 and is projected to reach USD 263.08 billion by 2037, witnessing around 11.7% CAGR during the forecast period i.e., between 2025-2037.

North America industry is likely to account for largest revenue share by 2037, impelled by efficient healthcare sector, supported by high government investment.

The major players in the market are PerkinElmer Inc., Biomarker Technologies, Inc., Almac Group Limited, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Epigenomics AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN GmbH and others.

Diagnostic Biomarkers Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos